By 2050, 30% of European citizens will be over 65, and 10% will surpass the age of 80. While life expectancy has increased by 30 years over the past century, this extended longevity often comes with more years lived with chronic diseases, particularly cardiovascular conditions.
A key factor in ageing is the loss of arterial elasticity, a phenomenon that can lead to serious conditions such as hypertension, atherosclerosis, aneurysms, heart failure, and neurovascular disorders associated with Alzheimer’s disease.
The JuvenTwin project aims to understand and counteract the mechanisms behind arterial stiffening. By leveraging advanced “digital twins,” it seeks to unravel the mechanobiological processes at the cellular level to delay or even reverse the effects of arterial ageing.
The project focuses on four major objectives:
- Identifying the impacts of ageing on arterial wall cells.
- Investigating the mechanobiological interactions influencing these cells.
- Simulating these processes at the systemic level for a deeper understanding.
- Developing innovative therapies to preserve or restore arterial health.
By harnessing cutting-edge technologies such as artificial intelligence, interferometry, and advanced mathematical models, JuvenTwin aims to develop revolutionary treatments by 2030. The ultimate goal is to extend vascular health and significantly enhance the quality of life for older individuals.